symptomatic

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 52/100

   A Severe Symptomatic Case of Amyloid-Related Imaging Abnormalities After Donanemab Infusion

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Cureus · 2026-05-17 · Treatments

   Amyloid-related imaging abnormalities (ARIA) are known complications of anti-amyloid monoclonal antibody therapy for Alzheimer's disease.

   • Treatments
   • Side Effects
   • Brain Scans
2. 48/100

   Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease reports · 2026-01-01 · Treatments

   Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease.

   • Treatments
   • Side Effects
3. 79/100

   Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported cases

   ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Journal of Alzheimer's disease : JAD · 2025-12-12 · Treatments

   BackgroundAmyloid-related imaging abnormalities (ARIA) are a recognized complication of anti-amyloid monoclonal antibodies for Alzheimer's disease (AD).

   • Treatments
   • Side Effects
   • Brain Scans
4. 45/100

   An Update of the Treatment Landscape for Alzheimer's Disease: From Symptomatic Treatments to the Emergence of Amyloid-Targeting Therapies

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Sage open aging · 2025-01-01 · Treatments

   Several approved Alzheimer's disease (AD) treatments help manage its associated cognitive symptoms (e.g., donepezil and memantine) or non-cognitive symptoms.

   • Treatments
   • Side Effects
5. 69/100

   Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study

   ✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Lancet. Neurology · 2024-12-01 · Brain scans and imaging

   Generalised linear regressions showed significant quadratic associations between amyloid age and cognitive performance and cubic associations between amyloid age and tau, both at baseline and at the 32-month follow-up.

   • Brain Scans
6. 43/100

   Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences · 2023-09-09 · Treatments

   In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people.

   • Treatments
   • Brain Biology
7. 64/100

   A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease

   ✓ Peer-reviewed alzhub usefulness score 64 out of 100. The journal of prevention of Alzheimer's disease · 2022-01-01 · Biomarkers

   These findings support use of U-p53AZ as blood-based biomarker predicting whether individuals would reach neuropsychologically-defined AD within six years prior to AD diagnosis.

   • Biomarkers
   • Brain Scans
   • Genetics

All topic tags with their study counts